Search results
Results from the WOW.Com Content Network
A hexavalent vaccine, or 6-in-1 vaccine, is a combination vaccine with six individual vaccines conjugated into one, intended to protect people from multiple diseases. [1] [9] The term usually refers to the children's vaccine that protects against diphtheria, tetanus, pertussis, poliomyelitis, haemophilus B, and hepatitis B, [1] [9] which is used in more than 90 countries around the world ...
The preferred age for MenB vaccination is 16 through 18 years of age. (Category B)” [6] The motion was passed, 14 to 1. In 2020 ACIP created a phased vaccine allocation recommendation for the COVID vaccines. [15] [16] [17] In the 2024 case of Braidwood v.
Zapomeran, sold under the brand name Kostaive is a self-amplifying mRNA-based COVID-19 vaccine. [1] It contains a self-amplifying mRNA that encodes the SARS-CoV-2 spike protein. [ 1 ] Self-amplifying means that the mRNA also carries instructions to make a protein called replicase .
Prolene is a brand of synthetic polypropylene used in monofilament nonabsorbable sutures and meshes. The suture is indicated for skin closure and general soft tissue approximation and ligation. Its advantages include minimal tissue reactivity and durability.
A pentavalent vaccine combines five vaccines into one dose. Pentavalent vaccines include: DTwP-HepB-Hib vaccine, used by UNICEF in low/middle income countries; DTaP-IPV/Hib vaccine, used in the UK until 2017 (replaced by a hexavalent vaccine) DTaP-IPV-HepB vaccine, approved in the US
CoVLP (brand name Covifenz) was a COVID-19 vaccine developed by Medicago in Canada and GlaxoSmithKline (GSK). The product and Medicago, Inc. were owned by Mitsubishi who terminated the company and program in February 2023 due to high international market competition for COVID-19 vaccines. [6]
Modified vaccinia Ankara (MVA) is an attenuated (weakened) strain of the vaccinia virus. It is being used as a vaccine (called MVA-BN, brand names: Imvanex in the EU, [3] Imvamune in Canada, [2] and Jynneos in the US [1]) against smallpox and mpox, [4] having fewer side effects than smallpox vaccines derived from other poxviruses.
In April 2021, the Indian Council of Medical Research reported that the vaccine has shown promising results in neutralising lineage B.1.617. [54] [55] In May 2021, a joint investigation by the scientists of the National Institute of Virology, found the vaccine effective in neutralising the Zeta variant or lineage P.2 (previously known as B.1.1. ...